CN107519174A - A kind of new compound preparation of ceftiofur sodium - Google Patents
A kind of new compound preparation of ceftiofur sodium Download PDFInfo
- Publication number
- CN107519174A CN107519174A CN201710824043.5A CN201710824043A CN107519174A CN 107519174 A CN107519174 A CN 107519174A CN 201710824043 A CN201710824043 A CN 201710824043A CN 107519174 A CN107519174 A CN 107519174A
- Authority
- CN
- China
- Prior art keywords
- parts
- sodium
- ceftiofur sodium
- compound preparation
- new compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of new compound preparation of ceftiofur sodium, 2 10 parts of ceftiofur sodium, 15 parts of fosfomycin sodium, 13 parts of sulbactam, 47 parts of superfine silica gel powder, 13 parts of lecithin, 0.2 1 parts of fatty acid sorbitan, 0.2 1 parts of polysorbate.The present invention is by Test Summary for many years, and according to antibacterials synergy principle, the new compound preparation of ceftiofur sodium of compatibility, cause illness with prevention Escherichia coli and salmonella so as to the treatment of Mutiple Targets, and with folk prescription comparable amount, improving its antibacterial activity, and overcome the drug resistance problems of Escherichia coli and salmonella, while application, the survival rate of domestic animal is improved.
Description
Technical field
The invention belongs to field of medicine and chemical technology, and in particular to a kind of new compound preparation of ceftiofur sodium.
Background technology
Colibacillosis is to cause the acute or chronic bacillary of livestock and poultry by some bacterial strains of pathogenic ETEC
Infectious disease.At present, the disease is increasingly taken seriously as a kind of potential zoonosis in public health.Due to its antigen
Property it is complicated, serotype is various, and clinical symptoms and pathological change are changeable, and more concurrent with viral disease and other bacteriosises
Or it is secondary, bring sizable harm to livestock and poultry breeding industry particularly pig industry and poultry husbandry.Clinically due to cause of disease serotype
It is extremely more to cause a variety of different diseases, the common white scour of piglet, piglet yellow scour on pig, there are higher morbidity and mortality,
Mainly pass through transmission, common e. coli septicemia, yolk peritonitis on chicken, major transmission path include disappearing
Change road, respiratory tract, eggshell penetrate, mate, through egg vertical transmission etc..
Salmonellal acute infectious disease according to clinical manifestation can be divided into gastroenteritis type (poison by food), typhoid fever type,
Septicemia type and parenterally focal infection.It is wherein most commonly seen with gastroenteritis type, can cause Nausea and vomiting, stomachache, diarrhoea and
The clinical signs groups such as heating.Salmonella choleraesuls are found that in salmonella earliest, 1885 by U.S. bacteriologist
D.E. Sa Meng (sramana) isolates from the pig of affected pig cholera, hence obtains one's name.Salmonella is mainly animal pathogen, can
Cause necrotic enteritis, white diarrhea, fowl typhoid etc., but also the mankind can be infected by approach such as contaminated food products or water sources, turn into people
The conditioned pathogen of class, such as salmonella typhimurium, Bacterium enteritidis, Salmonella choleraesuls.It is only right in salmonella
The mankind have pathogenic such as salmonella typhi, salmonella paratyphi.Food transmission is mankind's salmonella infection
Main path.In nature, salmonella has extensive animal host.The poultry such as chicken, duck, goose and pig, ox, sheep, Ma Dengjia
Poultry, and various beasts, fish, muroid can carry disease germs, or even also may separate out salmonella from cicada and some insects.This bacterium
Be present in the enteric cavity of these animals, thus in poultry domestic animals slaughter, process its meat can microbiological contamination, infected animal butchers
After sell be more easy to propagate germ, eggs or egg products can equally be polluted.
Many antibiotic such as aminoglycoside, chloromycetin, quinolones all have necessarily to Escherichia coli and salmonella
The effect of, but easily produce drug resistance.In recent years, due to these antibiotic it is a large amount of it is lack of standardization use and abuse, antibody-resistant bacterium
It is a large amount of to produce, often result in therapeutic effect unobvious.
Ceftiofur sodium is that special third generation cephalosporin antibacterial activity is extremely strong, to gram-positive bacteria, negative bacterium and is detested
Oxygen bacterium, have and be efficiently not likely to produce drug resistance, long half time, lasting medicine.Ratify injection first from U.S. FDA in 1988
Since ceftiofur sodium is used to treat ox infection in respiratory system, its veterinary clinic application at home and abroad is increasingly extensive.
But with the use frequently use with heavy dose of ceftiofur sodium so that ceftiofur sodium action potency reduces,
Drug resistance is even produced, have impact on the application of ceftiofur sodium, especially to the drug resistance of Escherichia coli and salmonella particularly
Seriously, do not have fine solution now.Applicant passes through Test Summary for many years, and former according to antibacterials synergy
Then, the new compound preparation of ceftiofur sodium of compatibility, it efficiently solves the drug resistance problems of Escherichia coli and salmonella,
While improving action effect and application, the survival rate of domestic animals and fowls is improved.
The content of the invention
In view of the above-mentioned deficiencies in the prior art, it is an object of the present invention to now provide a kind of new compound preparation of ceftiofur sodium.
In order to solve the above technical problems, the technical solution adopted by the present invention is：A kind of new compound preparation of ceftiofur sodium,
Its innovative point is：Ceftiofur sodium 2-10 parts, fosfomycin sodium 1-5 parts, sulbactam 1-3 parts, superfine silica gel powder 4-7 parts, lecithin
Fat 1-3 parts, fatty acid sorbitan 0.2-1 parts, polysorbate 0.2-1 parts.
Further, 2 parts of ceftiofur sodium, 1 part of fosfomycin sodium, 1 part of sulbactam, 4 parts of superfine silica gel powder, 1 part of lecithin,
0.2 part of fatty acid sorbitan, 0.2 part of polysorbate.
Further, 10 parts of ceftiofur sodium, 5 parts of fosfomycin sodium, 3 parts of sulbactam, 7 parts of superfine silica gel powder, lecithin 3
Part, 1 part of fatty acid sorbitan, 1 part of polysorbate.
Further, 6 parts of ceftiofur sodium, 3 parts of fosfomycin sodium, 2 parts of sulbactam, 5.5 parts of superfine silica gel powder, lecithin 2
Part, 0.6 part of fatty acid sorbitan, 0.6 part of polysorbate.
Beneficial effects of the present invention are as follows：The present invention passes through Test Summary for many years, and former according to antibacterials synergy
Then, the new compound preparation of ceftiofur sodium of compatibility, cause so as to the treatment of Mutiple Targets with preventing Escherichia coli and salmonella
Illness, and with folk prescription comparable amount, improving its antibacterial activity, and overcome the resistance to of Escherichia coli and salmonella
Property of medicine problem, while application, improve the survival rate of domestic animal.
Embodiment
Embodiments of the present invention are illustrated by particular specific embodiment below, those skilled in the art can be by this explanation
Content disclosed by book understands other advantages and effect of the present invention easily.
A kind of new compound preparation of ceftiofur sodium, ceftiofur sodium 2-10 parts, fosfomycin sodium 1-5 parts, sulbactam 1-3
Part, superfine silica gel powder 4-7 parts, lecithin 1-3 parts, fatty acid sorbitan 0.2-1 parts, polysorbate 0.2-1 parts.
Embodiment 1
A kind of new compound preparation of ceftiofur sodium, 2 parts of ceftiofur sodium, 1 part of fosfomycin sodium, 1 part of sulbactam, superfine silica gel powder
4 parts, 1 part of lecithin, 0.2 part of fatty acid sorbitan, 0.2 part of polysorbate.
Embodiment 2
A kind of new compound preparation of ceftiofur sodium, 10 parts of ceftiofur sodium, 5 parts of fosfomycin sodium, 3 parts of sulbactam, micro mist silicon
7 parts of glue, 3 parts of lecithin, 1 part of fatty acid sorbitan, 1 part of polysorbate.
Embodiment 3
A kind of new compound preparation of ceftiofur sodium, 6 parts of ceftiofur sodium, 3 parts of fosfomycin sodium, 2 parts of sulbactam, superfine silica gel powder
5.5 parts, 2 parts of lecithin, 0.6 part of fatty acid sorbitan, 0.6 part of polysorbate.
The present invention acts synergistically principle by Test Summary for many years, and according to antibacterials, the new Ceftiofur of compatibility
Sodium compound preparation, cause illness so as to treatment and the prevention Escherichia coli and salmonella of Mutiple Targets, and similar to folk prescription
Under dosage, its antibacterial activity is improved, and overcomes the drug resistance problems of Escherichia coli and salmonella, while using
Scope, improve the survival rate of domestic animal.
Above-described embodiment is presently preferred embodiments of the present invention, is not the limitation to technical solution of the present invention, as long as
The technical scheme that can be realized on the basis of above-described embodiment without creative work, it is regarded as falling into patent of the present invention
Rights protection scope in.
Claims (4)
- A kind of 1. new compound preparation of ceftiofur sodium, it is characterised in that：Ceftiofur sodium 2-10 parts, fosfomycin sodium 1-5 parts, relax Batan sodium 1-3 parts, superfine silica gel powder 4-7 parts, lecithin 1-3 parts, fatty acid sorbitan 0.2-1 parts, polysorbate 0.2-1 parts.
- A kind of 2. new compound preparation of ceftiofur sodium according to claim 1, it is characterised in that：2 parts of ceftiofur sodium, 1 part of fosfomycin sodium, 1 part of sulbactam, 4 parts of superfine silica gel powder, 1 part of lecithin, 0.2 part of fatty acid sorbitan, polysorbate 0.2 Part.
- A kind of 3. new compound preparation of ceftiofur sodium according to claim 1, it is characterised in that：Ceftiofur sodium 10 Part, 5 parts of fosfomycin sodium, 3 parts of sulbactam, 7 parts of superfine silica gel powder, 3 parts of lecithin, 1 part of fatty acid sorbitan, 1 part of polysorbate.
- A kind of 4. new compound preparation of ceftiofur sodium according to claim 1, it is characterised in that：6 parts of ceftiofur sodium, 3 parts of fosfomycin sodium, 2 parts of sulbactam, 5.5 parts of superfine silica gel powder, 2 parts of lecithin, 0.6 part of fatty acid sorbitan, polysorbate 0.6 Part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710824043.5A CN107519174A (en) | 2017-09-13 | 2017-09-13 | A kind of new compound preparation of ceftiofur sodium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710824043.5A CN107519174A (en) | 2017-09-13 | 2017-09-13 | A kind of new compound preparation of ceftiofur sodium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107519174A true CN107519174A (en) | 2017-12-29 |
Family
ID=60735907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710824043.5A Pending CN107519174A (en) | 2017-09-13 | 2017-09-13 | A kind of new compound preparation of ceftiofur sodium |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107519174A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101879172A (en) * | 2010-07-13 | 2010-11-10 | 杨建彬 | Compound preparation of ceftiofur sodium |
| CN104352455A (en) * | 2014-11-13 | 2015-02-18 | 重庆泰通动物药业有限公司 | Cefalexin injection |
-
2017
- 2017-09-13 CN CN201710824043.5A patent/CN107519174A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101879172A (en) * | 2010-07-13 | 2010-11-10 | 杨建彬 | Compound preparation of ceftiofur sodium |
| CN104352455A (en) * | 2014-11-13 | 2015-02-18 | 重庆泰通动物药业有限公司 | Cefalexin injection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103948930B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and beta-lactam antimicrobial drug | |
| CN103989728A (en) | Acalypha australis L. and beta-lactam antibacterial medicine containing compound medicine for livestock and poultry | |
| CN103989725A (en) | Acalypha australis L. and amikacin containing compound medicine for livestock and poultry | |
| CN103961421A (en) | Compound medicine containing radix paeoniae rubra and mequindox for livestock and poultry | |
| CN101879172B (en) | Compound preparation of ceftiofur sodium | |
| Peng et al. | Animal health: global antibiotic issues | |
| CN103977089B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fosfomycin | |
| CN103989727A (en) | Acalypha australis L. and mequindox containing compound medicine for livestock and poultry | |
| Jahantigh et al. | Antimicrobial drug resistance pattern of Escherichia coli isolated from chickens farms with colibacillosis infection | |
| CN103948692B (en) | A kind of livestock and poultry compound medicine containing the radix paeoniae rubrathe and amikacin | |
| CN103989731A (en) | Acalypha australis L. and florfenicol containing compound medicine for livestock and poultry | |
| CN103989729A (en) | Acalypha australis L. and sulfamonomethoxine sodium containing compound medicine for livestock and poultry | |
| CN103948691B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and sulfamonomethoxine sodium | |
| CN104306420A (en) | Balsamiferou blumea herb and sulfamonomethoxine sodium containing compound medicine for livestock and poultry | |
| CN103989726A (en) | Acalypha australis L. and fosfomycin containing compound medicine for livestock and poultry | |
| CN101744827B (en) | Medicinal composition for killing chicken colibacillosis and preparation method and use thereof | |
| CN104337847B (en) | A kind of livestock and poultry compound medicine containing phoenix-tail fern and phosphonomycin | |
| CN104367601A (en) | Compound medicine containing herba pteridis multifidae and mequindox for livestock and poultry | |
| CN107519174A (en) | A kind of new compound preparation of ceftiofur sodium | |
| CN104435012A (en) | Pteris multifida and florfenicol-containing compound drug for livestock and poultry | |
| CN107595852A (en) | A kind of new compound preparation of ceftiofur sodium | |
| CN107569489A (en) | A kind of compound preparation of ceftiofur sodium | |
| CN102764252A (en) | Application of valnemulin hydrochloride | |
| CN104306422A (en) | Balsamiferou Blumea herb and beta-lactam antibacterial drug containing compound medicine for livestock and poultry | |
| CN104435038A (en) | Balsamiferou blumea herb and mequindox containing compound medicine for livestock and poultry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171229 |
|
| WD01 | Invention patent application deemed withdrawn after publication |